ArticleAnnals of surgical oncology2025
Laparoscopic Extended Segmentectomy 8 with Right Hepatic Vein Resection After Conversion Therapy for Advanced Intrahepatic Cholangiocarcinoma.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Salvage resection for FGFR2 fusion-positive intrahepatic cholangiocarcinoma after pemigatinib therapy: a case report and literature review.Frontiers in oncology · 2026Article
- Surgery vs. non-surgery for advanced cholangiocarcinoma post-conversion therapy with PD-1/PD-L1 inhibitors plus TKIs.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundMost patients with intrahepatic cholangiocarcinoma (ICC) are diagnosed at advanced stages and are thus ineligible for surgery. Recently, a combination of immunotherapy, chemotherapy, and lenvatinib has shown promising results for treating advanced ICC.
methodsA 54-year-old patient was found to have a hepatic tumor in segment 8, with invasion into the right hepatic vein and multiple enlarged lymph nodes, confirmed by abdominal computed tomography (CT). After six cycles of conversion therapy, partial response was achieved. The patient then underwent laparoscopic extended segmentectomy 8 and right hepatic vein resection. Preoperative planning with three-dimensional (3D) reconstruction, along with intraoperative ultrasonography and ICG-guided fluorescent staining, greatly enhanced the precision and success of the surgery.
resultsThe operation lasted 220 min with an estimated blood loss of 800 mL. The Pringle maneuver was performed intermittently six times for a total of 85 min. The patient was discharged on the 12th postoperative day without complications. Postoperatively, the patient received adjuvant therapy with durvalumab and capecitabine,
conclusionsCases of patients with advanced ICC undergoing surgical resection after immunotherapy and chemotherapy are rare. The combination of GEMOX, durvalumab, and lenvatinib showed promising antitumor efficacy and safety, suggesting its potential as a feasible and safe conversion therapy for advanced ICC.
Indexed as
Identifiers
40397343What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.